The traditional PSA test has limited specificity, meaning that elevated levels of PSA can result from benign conditions such as benign prostatic hyperplasia (BPH) and prostatitis, leading to unnecessary biopsies. The phi test offers a more accurate risk stratification, helping to identify men who are more likely to have prostate cancer and thus should undergo further investigation. This reduces the number of unnecessary biopsies and associated complications.
